Stock News

Company Update (NASDAQ:CRIS): Curis Prices Public Offering of Common Stock

Curis, Inc. (Nasdaq:CRIS), announced the pricing of an underwritten registered public offering of 21,818,181 shares of its common stock at a public offering price …

Company Update (NASDAQ:CRIS): Curis Announces Proposed Public Offering of Common Stock

Curis, Inc. (NASDAQ:CRIS), announced that it has commenced an underwritten public offering of shares of its common stock.

Stock Update (NASDAQ:EXEL): Exelixis Announces Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update

Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and full year of 2014 and provided an update on progress toward …

Company Update (NASDAQ:MNKD): MannKind Corporation Reports 2014 Fourth Quarter and Full Year Financial Results

MannKind Corporation (NADSAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2014. For the fourth quarter, our …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that it is offering 7.

ISIS Pharmaceuticals Reports ISIS-PKK Positive Phase 1 Data In Prekallikrein Levels

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced positive results from a Phase 1 study with ISIS-PKKRx.

Stock Update (NASDAQ:GALT): Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02

Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces details of the design of its …

Stock Update (NASDAQ:CYTX): Cytori Receives Positive European Opinion on Orphan Drug Status

Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) issued a positive opinion toward Cytori’s …

Stock Update (NASDAQ:EXAS): Exact Sciences Reports Fourth-Quarter and Full-Year 2014 Financial Results

Exact Sciences Corp. (Nasdaq:EXAS) announced its financial results for the quarter and year ended Dec.

Stock Update (NASDAQ:CLDX): Celldex Reports Fourth Quarter and Year-End 2014 Results

Celldex Therapeutics, Inc. (Nasdaq:CLDX) reported business and financial highlights for the fourth quarter and year ended December 31, 2014.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts